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Background: The Loeys-Dietz syndrome (LDS) is a rare autosomal dominant disorder characterized by thoracic
aortic aneurysm and dissection and widespread systemic connective tissue involvement. LDS type 1 to 4 are caused
by mutations in genes of the TGF-β signaling pathway: TGFBR1 and TGFBR2 encoding the TGF-β receptor (LDS1 and
LDS2), SMAD3 encoding the TGF-β receptor cytoplasmic effector (LDS3), and TGFB2 encoding the TGF-β2 ligand
(LDS4). LDS4 represents the mildest end of the LDS spectrum, since aneurysms are usually observed in fourth
decade and the progression of the disease is slower than in the other forms.
Case presentation: We report the clinical and molecular findings of an LDS4 Italian family. Genetic testing
included TGFBR1, TGFBR2, SMAD3, and TGFB2 analysis by Sanger sequencing. In order to verify the effect of the
identified splice mutation, RT-PCR analysis was performed.
The proband, a 57-year-old woman, showed high palate, hypoplasic uvula, easy bruising, joint hypermobility, chronic
pain, scoliosis, multiple relapsing hernias, dural ectasia, and mitral valve prolapse. Magnetic resonance angiography
revealed tortuosity and ectasia of carotid, vertebral, cerebral, and segmental pulmonary arteries. Arterial aneurysm and
dissection never occurred. Her 39- and 34-year-old daughters presented with a variable degree of musculoskeletal
involvement. Molecular analysis disclosed the novel c.839-1G>A splice site mutation in the TGFB2 gene. This mutation
activates a cryptic splice acceptor site in exon 6 leading to frameshift, premature termination codon and
haploinsufficiency (p.Gly280Aspfs*41).
Conclusions: Our data confirm that loss-of-function mutations in TGFB2 gene do not always lead to aggressive
vascular phenotypes and that articular and skeletal signs are prevalent, therefore suggesting that LDS4 must be
considered in patients with sparse signs of LDS and related disorders also in the absence of vascular events.
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Thoracic Aortic Aneurysms and Dissections (TAADs) are
a common cause of sudden death of young adults. The
pathophysiology of TAAD is complex and multi-factorial.
To date, though classic cardiovascular risk factors play a
pivotal role in a majority of patients, several genes have
been identified in both syndromic and nonsyndromic
forms of TAAD, including FBN1 (Marfan syndrome, MFS)* Correspondence: marina.colombi@unibs.it
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unless otherwise stated.[1], TGFBR1, TGFBR2 [2,3] and SMAD3 (Loeys-Dietz syn-
drome type 1 to 3, LDS) [4], SLC2A10 (Arterial tortuosity
syndrome, ATS) [5], ACTA2 (TAAD with livedo reticularis
and iris flocculi) [6], MYH11 (TAAD with patent ductus
arteriosus) [7], and MYLK (TAAD7) [8]. Although clinical
features show significant overlap, these entities differ in the
extent of vascular involvement and clinical course and, as
a consequence, molecular characterization has become
crucial in the evaluation, counseling and management of
these patients. Among the syndromic forms of TAAD,
LDS is a rare autosomal dominant disorder with wide-
spread systemic involvement and connective tissuetd. This is an Open Access article distributed under the terms of the Creative
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and type 2 (LDS2, MIM#610168) are caused by heterozy-
gous mutations in the genes encoding the TGF-ß recep-
tors type 1 and 2, which bind TGF-β and initiate cellular
signaling [2,3]. The majority of individuals with LDS1 and
2 shows vascular findings with life-threatening complica-
tions, such as aortic dissection and widespread aortic
aneurysms, and life expectancy is reported to be 37 years
[9,10]. Craniofacial signs as ocular hypertelorism, bifid
uvula/cleft palate or craniosynostosis and cutaneous
manifestations, as velvety and translucent skin, easy
bruising, atrophic scars, are also present at variable
degree [2,3,9,11]. In the first reports, LDS patients
were stratified into 2 types, depending on severity of
craniofacial features (type 1) or cutaneous features
(type 2). However, these findings are now believed to
be part of a continuum within the LDS spectrum of
disease [12]. Mutations in the SMAD3 gene, which
encodes a protein critical for cellular signaling down-
stream of the TGF-β receptors after ligand binding, are
responsible for LDS type 3 (LDS3, MIM#613795), also
known as Aneurysms–Osteoarthritis Syndrome. LDS3
patients share phenotypic manifestations with LDS1
and 2, i.e., aortic root aneurysm, vascular dissection,
skeletal deformities, and typically show osteoarthritis
at young age [13,14], although families without osteo-
arthritis are also reported [15].
Lindsay et al. and Boileau et al. identified an additional
gene responsible for familial TAAD, the TGFB2 gene,
which encodes the ligand TGF-β2 [16,17]. In particular,
Boileau et al. discovered heterozygous mutations in 2
families and 2 sporadic cases with TAA [17], and Lindsay
et al. identified TGFB2 mutations in 8 families [16]. Both
groups examined aortic tissue from probands and found
fragmentation of elastin fibers and deposition of collagen
and proteoglycans, similar to what is observed in tissues
from MFS and LDS patients. Furthermore, altered TGF-β
signaling, as judged by an increase in TGF-β1 or TGF-β2
protein expression and greater nuclear accumulation of
phosphorylated SMAD2, was demonstrated. In TGFB2
heterozygous knockout (Tgfb2+/−) mice Lindsay et al.
found aortic root dilatation and increased TGF-β signaling,
consistent with the human disease presentation [16].
Careful clinical phenotyping of TGFB2 mutation-bearing
individuals identified a variety of vascular, musculoskeletal,
and other features shared by patients with either MSF
or LDS, therefore, the disorder was classified as LDS4
(MIM#614816). Features shared with MFS and LDS
include aortic aneurysm, mainly in thoracic tract, pectus
deformity, arachnodactyly, scoliosis, joint hypermobility,
and striae distensae in young age. Features shared with
LDS, but not MFS, include hypertelorism, bifid uvula,
bicuspid aortic valve, mitral valve prolapse (MVP), arterial
tortuosity, club feet, and thin skin with easy bruising [16].In LDS4 aortic aneurysm presents at later onset; relatively
mild aortic dilatation, mainly at the level of the sinus of
Valsalva, and a lower incidence of dissection compared to
the other LDS types was observed, and the reported mean
age of aortic disease was 35 years [17]. Renard et al.
described other 6 sporadic LDS4 patients with TGFB2
mutations, pointing out a high rate of mitral valve disease,
suggesting that this might be a signature feature of the
disorder that may direct molecular analysis [18]. Leuter-
mann et al., very recently described another LDS4 family
with three affected members [19]. Recently a revised LDS
nosology was proposed, in particular the authors suggested
that a mutation in any of these 4 genes in combination with
documented aneurysms or dissection should be sufficient
for the diagnosis of LDS [20].
Here, we report on a new LDS4 family with a 57-
year-old proband without thoracic aortic aneurysms
and other major vascular complications, caused by a
novel mutation in the TGFB2 gene and compare the
clinical features of the affected members with those re-
ported in the literature. Our data suggest that LDS4 must
be considered in patients with sparse signs of LDS and re-
lated disorders, also in the absence of vascular events.
Case presentation
Patients, materials and methods
We describe an Italian LDS4 family with three affected
members: the proposita and her 34-year-old daughter,
underwent careful clinical evaluation and provided writ-
ten informed consent for genetic testing. The clinical
features of the 39-year-old daughter were reported by
the proposita, since this daughter did not consent clinical
evaluation and genetic testing, likewise both proband’s
parents, in the octave decade and with a referred unre-
markable clinical history, could not be evaluated.
The proposita underwent extensive cardiovascular stud-
ies, including electrocardiogram (ECG), echocardiography,
and brain, thoracic and abdominal magnetic resonance
angiography (MRA). The 34-year-old daughter did not con-
sent MRA study and only ECG and echocardiography with
aortic root evaluation were performed. Genomic DNA was
purified from blood samples using Wizard Genomic DNA
purification Kit (Promega) by standard procedures. Total
RNA was isolated from proband’s whole blood using
NucleoSpin® RNA Blood Midi Kit (Macherey-Nagel) and
retrotranscribed in the presence of random hexanu-
cleotide primers and MMLV-RTase (Life Technologies)
by standard procedures. Primers were designed for all
coding exons, including their intron–exon boundaries,
and for the 5′ and 3′ UTRs near the coding sequence
(a minimum of 200 bp), using the Primer3 tool (http://
frodo.wi.mit.edu/). Primer sequences were checked
for the absence of known variants, such as single nu-
cleotide polymorphisms, based on dbSNP version 139
Ritelli et al. BMC Medical Genetics 2014, 15:91 Page 3 of 9
http://www.biomedcentral.com/1471-2350/15/91(www.ncbi.nlm.nih.gov/projects/SNP/). In particular, all
exons and intron flanking regions of TGFBR1, TGFBR2,
SMAD3 and TGFB2 genes were amplified by standardized
PCR using optimized genomic primer-sets and the GoTaq
Ready Mix 2X (Promega) (primer sequences and amp-
lification profiles are available upon request). After en-
zymatic cleanup of the PCR products by ExoSap-IT®
(Affymetrix), all fragments were sequenced in both orien-
tations using the BigDye® Terminator Cycle Sequencing
kit protocol (Life Technologies) and the Performa® DTR
Ultra 96-Well Plates (EdgeBio) for PCR cleanup followed
by capillary electrophoresis on the ABI3130XL Genetic
analyzer (Life Technologies). The identified TGFB2 muta-
tion was not found in 100 control individuals or in the
1000 Genomes Project or NHLBI Exome Variant Server
(ESP6500) databases. Nucleotide and protein accession
numbers correspond to the TGFB2 (NM_000093.3,
NP_000084.3) reference sequences. The mutation was
annotated according to HGVS nomenclature (www.hgvs.
org/mutnomen), and the sequence description verified
using Mutalyzer (www.LOVD.nl/mutalyzer). Nucleotide
numbering was based on cDNA sequence numbering
with +1 corresponding to the A of the ATG translation
initiation codon 1 in the reference sequence. For protein
numbering, +1 corresponds to the first translated amino
acid. The sequences were analyzed using the Sequencher
4.9 software (www.genecodes.com). To evaluate the
identified splice site mutation, we used four prediction
programs (SpliceSite-Finder-like, MaxEntScan, NNSPLICE
and Human Splicing Finder) in the Alamut Software
version 2.4 (www.interactive-biosoftware.com). Further,
to verify the effect of the splice mutation, RT-PCR was
carried out by standard procedures; in particular, ampli-
fication of cDNA covering exons 5–7 of the TGFB2
gene was performed.
Clinical findings
The proposita (Figure 1A) was a 57-year-old woman
with family history remarkable for CTD in her two 39-
and 34-year-old daughters. She was born from unrelated
Italian parents after an uneventful pregnancy and deliv-
ery. Her perinatal and psychomotor development was
normal. Two pregnancies resulted in the birth of two
daughters. In the first pregnancy she reported premature
membrane rupture at 34 weeks, and in the second a
threatened abortion. The spontaneous menopause was
at 50 years. Clinical history presented widespread signs of
CTD. Since the childhood sub/luxations of the shoulders,
wrists, knees and ankles were occurring. She suffered from
acute articular rheumatism, diagnosed at 9 years, and right
relapsing inguinal hernia, surgically treated at 9, 25, and
40 years. Since her twenties, she referred chronic general-
ized articular pain, mainly affecting her back, treated with
NSAIDs. Magnetic resonance imaging (MRI), performedat 42 years, revealed dural ectasia, lumbar discal hernias
(L5-S1) and hypoplasia of the twelfth ribs (Figure 1B).
Clinical history also included crural hernia, surgically
treated at 25 and 40 years, hiatal hernia with gastroesoph-
ageal reflux, chronic headache, gingival fragility, and easy
bruising. Ectopia lentis was excluded by ophthalmologic
evaluation. ECG and echocardiography, performed at
49 years for tachycardia, discovered paroxysmal supraven-
tricular tachycardia and MVP with minimal regurgitation
and normal systolic function (EF 65%). Following this
analysis she underwent cryoablation therapy. At this age
the aortic root diameter was normal. On examination at
56 years, she presented with normal stature (1,63 m),
light blue sclerae, high arched palate, micrognathia,
elongated philtrum, hypoplasic uvula, doughy and hyper-
extensible skin over the neck, the forearm, and the elbows,
old aging aspect, striae distensae over the hips, joint
hypermobility according to Beighton score (9/9), and
scoliosis (Figure 1A). In a clinical suspicion of LDS, a
brain, thoracic and abdominal MRA was scheduled,
revealing tortuosity and ectasia of carotid, vertebral, and
cerebral arteries, and marked tortuosity of two segmental
pulmonary arteries (Figure 1B). No other vascular abnor-
malities were detected.
The proband reported that her first daughter presented
tall stature (1,76 m) for the familial target of 1,58 m,
hypotonia at birth, congenital talipes, umbilical hernia,
conservative treatment for scoliosis with orthopedic
corset at 13 years, chronic articular pain, recurrent
dislocations, flat feet, hallux valgus needing surgery,
easy bruising, and varicose veins. On evaluation at
34 years, the second daughter presented tall stature for
the familial target (1,78 m), high arched palate, myopia,
astigmatism, mild hyperextensible skin over the neck
and the elbows, atrophic post-surgical scar over the knee,
arachnodactyly, mild pectus excavatum, scoliosis, joint
hypermobility according to the Beighton score (6/9)
(Figure 1C). She referred recurrent right patella disloca-
tions, meniscus and lateral ligaments tear requiring
arthroscopic surgery in her youth, myopia, astigmatism,
easy bruising and Hashimoto thyroiditis. An ECG and
echocardiography revealed normal aortic root diameter,
therefore excluding ectasia or aneurysm at aortic root
level. Valvular system and systolic function (EF 75%) were
normal, except for MVP with minimal regurgitation.
Molecular characterization
After written informed consent of the proband, mutational
screening of the four LDS causative genes, i.e., TGFBR1,
TGBFR2, SMAD3 and TGFB2, was performed. This ana-
lysis revealed the presence of the novel c.839-1G>A splice
mutation in intron 5 of the TGFB2 gene, thus confirming
the diagnosis of LDS4 (Figure 2A). The causal mutation
was also found in the 34-year-proband’s daughter. All of
Figure 1 Clinical and radiological features of the proband and her daughter. (A) Clinical phenotype of the proband including microretrognathia,
and elongated philtrum (a, b), mild generalized skin hyperextensibility (c), joint hypermobility (d, e). (B) MRI in the proposita showed dural ectasia of
the lumbar tract (a), MRA disclosed tortuosity and ectasia of carotid, vertebral, and cerebral arteries (b, c) and marked tortuosity of both segmental
pulmonary arteries (d). (C) Clinical presentation of the 34 years-old proband’s daughter: hypotelorism, elongated philtrum and malar hypoplasia (a, b),
mild skin hyperextensibility over the neck (c), atrophic post-surgical scar and ecchymosis (d), arachnodactyly with positive wrist and thumb signs (e, f).
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predicted that the c.839-1G>A mutation abolishes the
canonical splice acceptor site. To verify the effect of the
splicing mutation, RT-PCR analysis was performed on
RNA purified from proband’s blood. Amplification of
the cDNA region covering exons 5–7 demonstrated that
the c.839-1G>A mutation leads to the activation of a cryp-
tic splice acceptor site 115 bp downstream of the consensus
site, generating a frameshift and a premature termination
codon formation (PTC) in exon 7 (p.Gly280Aspfs*41)
(Figure 2B). Furthermore, because of the lower amount
of the aberrant band, compared to the wild type transcript,
it is likely that the c.839-1G>A mutation activates to a cer-
tain degree the nonsense mediated RNA decay (NMD)
pathway, finally resulting in TGF-β2 haploinsufficiency
(Figure 2B).Discussion
LDS4 is a recently delineated autosomal dominant
condition presenting with aneurysms, dissections, and
tortuosity throughout the arterial tree in association
with mitral valve disease, mild craniofacial features, and
skeletal and cutaneous anomalies [16-19]. Mutations in the
TGFB2 gene accounted for 25% in Lindsay et al., 1.5% in
Boileau et al., 4% in Renard et al., and 1.1% in Leutermann
et al., of sampled familial cases of thoracic aortic disease
that were not attributed to other known TAAD-causing
genes [16-19]. So far, clinical data on LDS4 are available
in a limited number of cases, i.e., 11 families and 8 spor-
adic patients all carrying TGFB2 mutations (Table 1 and
Figure 3). Altogether, 15 independent mutations were
identified, 11 of which were whole-gene deletions,
frameshifts or nonsense mutations that were predicted
Figure 2 Molecular characterization of the proband. (A) The
sequence analysis of the TGFB2 gene disclosed the novel c.839-1G>A
transition (arrow), affecting the splice acceptor site of exon 6. (B)
Characterization of the splicing effect of the c.839-1G>A mutation:
agarose gel electrophoresis of the cDNA, amplified with primers
encompassing exons 5–7, showed in the patient (P) the presence of
an aberrant band (192 bp), in addition to the wild type fragment
(307 bp), which was also detected in the control (C). The sequencing
of the aberrant PCR product showed the deletion of the beginning
115 bp of exon 6 (r.839_953del), demonstrating that c.839-1G>A
mutation leads to the activation of a new cryptic splice acceptor site
between cDNA nucleotides 953 and 954.
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nate mRNA by NMD, and 4 were missense substitution
of highly conserved amino acids with a predicted patho-
logic effect. In the family here described, a novel spli-
cing mutation c.839-1G>A in intron 5 was identified in
the proband and in her daughter. Amplification of the
cDNA region covering exons 5–7 demonstrated that
the mutation leads to the activation of a cryptic splice
acceptor site within exon 6, that generates a PTC and
activates to a certain level the NMD pathway. As such,
the pathogenic mechanism underlying all the TGFB2
mutations is most likely loss-of-function.
Comparable to several other conditions known as
TGF-β vasculopathies and presenting with arterial an-
eurysms, such as MFS [21], the other LDS types [9] and
ATS [5], TGFB2 loss-of-function resulted in a activation in
TGF-β signaling pathway [22,23], as shown by the increase
of phosphorylated SMAD2 and SMAD3 (SMAD2/3) levelsin aortic lesions from TGFB2+/− patients and Tgfb2+/−
mice, as well as by elevated ligand levels of either TGF-β1
[16] or TGF-β2 [17].
Up to date a high incidence of TAA or ectasia, mainly
at the aortic root level, has been reported in LDS4
(Table 2). In particular, in Boileau et al. aortic root
aneurysm was detected in 74% of the cases (14/19) [17],
in Linsday et al. one main pulmonary artery aneurysm
was reported; but a Z-score >2 was detected in 93% of
the cases (14/15) [16]. In Renard et al. TAAs were
present in 67% of the cases (4/6), and in Leutermann et al.
aneurysms were present in two of the family members
[18,19]. Despite this high incidence of TAA or ectasia, a
lower rate and later onset of aortic dissection is noted in
LDS4 compared to other LDS types [9]. Considering the
LDS4 patients reported so far, an overall dissection rate
of 12% (5/43), at a median age of 46 years, emerged.
Specifically, in Boileau et al. the aortic dissection rate
was 11% (2/19 at 50 and 33 years), in Linsday et al. it
was 7% (1/15 at 42 years), and in Renard et al. 33% (2/6, at
60 and about 46 years) [16-18]. None of the clinically eval-
uated members of the family described by Leutermann
et al. had aortic dissections, but the proband (at 51 years)
and his brother (at 47 years) underwent aortic aneurysm
surgery and the index patient’s father died at 52 years after
acute aortic dissection [19]. Valve sparing aortic root
replacement (VSARR) for aortic root diameter between 45
and 56 mm was performed also in 20% of cases (3/15) in
Linsday et al., at a median age of about 41 years [16].
Cerebral arteries involvement was delineated only in
few cases; in particular, in Boileau et al. an anamnestic
cerebrovascular disease was reported in 30% of the cases
(3/10). Specifically, one episode of anterior communi-
cating artery aneurysm rupture and two internal carotid
aneurysm dissections were described; in the other 7 pa-
tients, investigated for neck and brain arteries, no aneurysm
was detected [17]. In Renard et al. a severe cerebrovascular
disease was documented in one patient, a 53-year-old
woman who suffered from recurrent TIA, since she was
18-year-old, recurrent strokes and presence of tortuous ver-
tebral arteries [18]. Lindsay et al. and Leutermann et al. did
not report cerebrovascular events [16,19].
The incidence of arterial tortuosity is not well docu-
mented, given the limited number of patient analyzed.
In particular, Boileau et al. found tortuosity in 3 out of 5
of the cases analyzed (14 patients were not investigated),
and Linsday et al. in 1 out of 4 of the analyzed cases (11
patients not investigated) [16,17]. Renard et al. identified
tortuosity of the vertebral arteries in the patient with
recurrent strokes, but it is unclear if the remaining
patients were studied [18]. Leutermann et al. reported
arterial tortuosity in both analyzed family members with
the proband showing profound cerebral and cervical
arterial tortuosity [19].
Table 1 Overview of currently known TGFB2 mutations
Exon ac-notation bp-notation Domain Reference
1 c.294_308del p.Ala100_Tyr104del LAP [16]
1 c.297C > A p.Tyr99* LAP [16]
1 c.304G > T p.Glu102* LAP [17]
3 c.475C > T p.Arg159* LAP [18]
5 c.771C > A p.Cys257* LAP [17]
6 c.839-1G > A p.Gly280Aspfs*41 LAP Current study
6 c.957_972dup p.Asn325* LAP [17]
6 c.979C > T p.Arg327Trp LAP [16,18]
6 c.980G > A p.Arg327Gln LAP [18]
6 c.988C > T p.Arg330Cys LAP [16]
7 c.1097C > A p.Pro366His Cyt [16]
7 c.1106_1110del p.Tyr369Cysfs*26 Cyt [16,17]
7 c.1125del p.Gly376Glufs*17 Cyt [18]
7 c.1165dupA p.Ser389Lysfs*8 Cyt [19]
Entire gene Chr1.hg19: g.(215,588,712)_(222,145,072)del [16]
Entire gene Chr1.hg19: g.(216,672,181)_(220,202,575)del [16]
aDNA mutation numbering is based on the cDNA sequence. For cDNA numbering, +1 corresponds to the A of the ATG translation initiation codon in the
reference sequence. The reference sequence is based on the GenBank Accession number: TGFB2 NM_001135599.2. bFor protein numbering, +1 corresponds to the
first translated amino acid. The reference sequence is based on the GenBank Accession number: TGFB2 NP_001129071.1. Abbreviations: LAP Latency-associated
peptide domain, Cyt TGF-β2 cytokine domain.
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daughter aortic dissection or cardiovascular surgery did
not occur and aortic aneurysms were not detected so
far. Although, we are conscious that the cardiovascular
phenotype of her daughter is incomplete, since no MRA
was performed, echocardiography excluded at least aortic
root involvement, the most common site of aneurysm in
LDS4 [16-19]. Furthermore, in the proband only a brain,
thoracic and abdominal MRA showed tortuosity and
ectasia of the carotid, vertebral, and cerebral arteries
and tortuosity of two segmental pulmonary arteries.
Thus, the vascular features of our family strengthen the
hypothesis of a milder vascular involvement in LDS4
compared to the other LDS types. Since a late-onsetFigure 3 Overview of currently known TGFB2 mutations. Exons and un
signal peptide is represented by a yellow, the Latency-Associated Peptide (
orange box. Frameshift/truncating mutations are listed at the bottom, whil
Boileau et al. [17] are in violet, those described by Lindsay et al. [16] in blue
green, the mutation reported in Leutermann et al. [19] is in black, and the
transcript NM_001135599.2 and protein reference sequence NP_001129071aneurysmatic vasculopathy remains possible, a periodical
follow-up with vascular imaging was scheduled for the
proband, and MRA study was highly recommended for
her daughter.
Concerning cardiovascular surgery, Boileau et al. de-
scribed 4 patients in the sixth decade, between them 3 were
admitted for thoracic aortic dissection at 47 years, for TAA
at 59 years and for MVP at 43 years (valve prosthesis) [17].
In Linsday et al., 2 patients were 50- and 61-year-old, and
the first underwent VSARR [16]. Finally, Renard et al. de-
scribed the oldest patient (69 years) who experienced a type
A aortic dissection surgically treated at 60 years [18]. Three
patients in sixth/seventh decade are also reported in this
article, one of them had mitral valve prosthesis at 56 yearstranslated regions (UTR) are represented by numbered boxes. The
LAP) domain by a green, and the TGF-β2 cytokine domain by an
e missense mutations are listed on the top. The mutations reported by
(# also reported by Boileau et al. [17]), those in Renard et al. [18] in
mutation identified in this study is in red. Numbering is based on
.1.
Table 2 Comparison of clinical findings between the current study and those of Boileau et al. [17], Lindsay et al. [16],
Renard et al. [18], and Leutermann et al. [19]
Frequencya
Clinical features Proband Daughter Boileau et al. [17] Lindsay et al. [16] Renard et al. [18] Leutermann et al. [19] Total/percentage
Cardiovascular
TAA or MPA - -c 14/19 1/4 (11) 4/6 2/2 (1) 21/32 (13) 65%
Aortic dissection - - 2/19 1/15 2/6 0/3 5/45 11%
Aortic repair - - 4/19 3/15 0/6 2/3 9/45 20%
Arterial tortuosity + N.A. 3/5 (14) 1/4 (11) 1/1 (5d) 2/2 (1) 8/13 (32) 61.5%
MV impaired + + 3/19 7/10 (5) 4/6 0/2 (1) 16/39 (6) 41%
Skeletal
Tall statureb - + 8/19 11/15 N.A. 2/2 (1) 22/38 (7) 58%
Pectus deformities - + 7/16 (3) 9/15 2/6 1/3 20/42 (3) 47.6%
Arachnodactyly - + 8/13 (6) 8/15 2/6 0/2 (1) 19/38 (7) 50%
Joint hypermobility + (BS 9/9) + (BS 6/9) 10/15 (4) 7/15 (BS > 5/9) 4/6 2/3 23/41 (4) 56%
Chronic Pain + + N.A. N.A. N.A. N.A. 2/2 (43)
Scoliosis + + 4/15 (4) 5/15 1/6 3/3 15/41 (4) 36.5%
Pes planus - - 11/15 (4) 8/15 1/6 2/2 (1) 22/40 (5) 55%
Club feet - - 0/15 (4) 5/15 1/6 0/2 (1) 6/40 (5) 15%
High arched palate + + 9/15 (4) 10/15 2/6 1/2 (1) 24/40 (5) 60%
Cutaneous
Hyperelastic skin + + 0/13 (6) N.A. N.A. N.A. 2/15 (30) 13%
Defective scaring - + N.A. 2/15 1/6 0/2 (1) 4/25 (20) 16%
Easy bruising + + N.A. 5/11 (4) N.A. 0/2 (1) 7/15 (30) 46.6%
Striae distensae + - 8/15 (4) 3/15 1/6 0/2 (1) 13/40 (5) 32.5%
Hernia + - 6/17 (2) 10/15 N.A. 2/2 (1) 19/36 (9) 52.7%
Other
Dural ectasia + N.A. 3/5 (14) 1/6 (9) N.A. 0/2 (1) 5/14 (31) 35.7%
aFeature present/number of evaluated patients; in parenthesis number of patients with no data available; b(>95th centile); cat aortic root level, ectasia and/or
aneurysm of ascending aorta, aortic arch and pulmonary artery were not ascertained; dit is unclear whether these 5 patients were investigated. BS: Beighton score;
N.A. not analyzed; MV: mitral valve; TAA: thoracic aortic aneurysm; MPA: main pulmonary artery aneurysm.
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proband and the mean number of cardiovascular sur-
geries or major cardiovascular events in the patients
over or in their sixth decade reported in literature, the
vascular involvement in LDS4 can be even milder than
described until now.
Since the tortuosity of the cerebral and neck arteries
disclosed in our proband is a predisposing condition for
aneurysm formation, we suggest that in LDS4 patients
the vascular screening should not be restricted only to
the thoracic arteries. An accurate evaluation of the brain
and neck arteries, also if they might be involved only in
a small percentage of patient, should be important in
order to prevent severe cerebrovascular events.
Our proband and her 34-year-old daughter showed
MVP, though with a low hemodynamic impairment, in
agreement with the hypothesis of Renard et al. that pointed
out a high rate of mitral valve disease, suggesting that thismight be a signature feature of the disorder [18]. On
the contrary, none of the family members reported by
Leutermann et al. showed mitral valve impairment,
suggesting that this hypothesis should be confirmed in
larger series [19].
Concerning the musculoskeletal involvement (Table 2),
Boileau et al. underlined a high rate of MFS signs, such
as pes planus (73% of cases, 11/15), high arched palate
(60% of the cases, 9/15), arachnodactyly (62% of cases,
8/13), and pectus deformities (44% cases, 7/16) [17].
Linsday et al., and Renard et al. confirmed the high
prevalence of these signs: pes planus rate was 53% (8/15)
and 17% (1/6) respectively; high arched palate rate was
67% (10/15) and 33% (2/6); arachnodactyly rate was 53%
(8/15) and 33% (2/6). Finally, pectus deformities rate was
60% (9/15) in Lindsay et al., and 33% (2/6) in Renard
et al. [16,18]. The musculoskeletal signs observed in the
family of Leutermann et al. were scoliosis (3/3), pes
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bility (2/3) [19]. Joint hypermobility was also present in
67% (10/15) of the cases in Boileau et al., in 47% (7/15) of
the cases in Linsday et al., and in 50% (3/6) of cases in
Renard et al. [16-18]. Skeletal signs of MFS were present
in all members of our family. A marphanoid habitus with
tall stature for the familial target, pectus excavatum, high
arched palate, and arachnodactyly were recognizable in
the 34-year-old daughter of the proband. In the 39-year-
old daughter tall stature for the familial target, pes planus
and scoliosis treated with orthopedic corset were referred.
The proband only showed scoliosis and high arched pal-
ate. Both patients of our family had a positive Beighton
score. Articular pain associated with joint hypermobility
was not reported in literature so far in patients with LDS4,
whereas both our patients referred chronic generalized
articular pain. In fact, the proposita and her daughter
came to our attention not for cardiovascular complains,
but mainly for joint hypermobility complications: chronic
articular pain since young age in the proposita, and
recurrent dislocations, either in the proposita and in
her daughter.
In our study, the neurological involvement, i.e., dural
ectasia, was monitored only in the proposita. While the
significance of dural ectasia is well recognized in MFS
[24,25], its prevalence in LDS is less well documented
[25,26]. Kono et al. showed that the occurrence of dural
ectasia in LDS1 and 2 was significantly higher than in
controls with a frequency that varied from 40 to 70%
[27]. The authors suggested that dural ectasia has the
potential to become a diagnostic criterion for LDS. In
support of this hypothesis, a recent comprehensive study
demonstrated that dural ectasia occurs in LDS with a
similar frequency and severity as in MFS [28]. Concern-
ing LDS4 patients, Boileau et al. found dural ectasia in 3
out of 5 patients, Linsday et al. in 1 out of 10, whereas
Leutermann et al., did not find this sign, and Renard et al.
did not investigate it [16-19]. Given the fact that the inci-
dence data of dural ectasia are limited to a small number
of LDS4 patients (5/14, with 31 patients not analyzed), its
presence should be studied in larger series of patients.
Conclusions
In conclusion, we suggest that LDS4 should be considered
in patients of all ages with variable but mostly mild LDS-
like phenotypes and/or with sparse signs of MFS and re-
lated connective tissue disorders with negative TGFBR1/2
and SMAD3 molecular tests, even though TAA and major
cardiovascular events are absent, as it was for our pro-
band. Molecular diagnosis allows the early identification
of patients and relatives at risk of major cardiovascular
complications. Further studies are needed to better delin-
eate the clinical phenotype of LDS4 and search for new
therapeutic options.Consent
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